US-based, clinical-stage biotechnology company Vaxart has begun the Phase I clinical trial of the oral norovirus tablet vaccine.

Vaxart’s vaccine delivery platform features a vector-adjuvant combination, which can be used with a range of recombinant antigens to develop orally administered vaccines.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase I trial is a randomised, double-blind, placebo-controlled, dose-ranging study designed to evaluate the safety and immunogenicity of Vaxart’s VP1, protein-based, norovirus tablet vaccine when administered to 66 healthy adult volunteers.

The participants will be observed for 12 months to determine safety, and other systemic and local immune responses to be examined at multiple time points during the study.

"We now have tablet vaccines in the clinic for norovirus, RSV and seasonal flu, three important pathogens with significant public health impact."

Vaxart CEO Wouter Latour said: “We now have tablet vaccines in the clinic for norovirus, RSV and seasonal flu, three important pathogens with significant public health impact.

See Also:

“A tablet vaccine for any of these indications would dramatically increase the efficiency of large vaccination campaigns improving vaccine uptake and reducing costs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Having all three would be the ultimate trifecta in the vaccine sector.”

Norovirus is considered as the chief cause in causing acute gastroenteritis, which triggers symptoms such as watery diarrhea, vomiting, abdominal cramps, nausea and sometimes fever.

According to Vaxart founder and chief scientific officer Sean Tucker, its norovirus tablet vaccine can immunise a larger population.

The vaccine is expected to induce systemic and local immune responses in the gut, which is believed to actively protect against a norovirus infection.